Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy: 2nd Gen ALK TKIs Alectinib & Brigatinib, and BFAST NGS Screening Workflow

163 views
March 18, 2021
0 Comments
Login to view comments. Click here to Login